Eli Lilly’s weight loss drug, tirzepatide, has shown remarkable results in reducing the risk of Type 2 diabetes by 94% for overweight individuals, based on a new three-year study.

The study, which involved more than 1,000 prediabetic patients, found that those taking the highest dose of 15 mg lost 23% of their body weight, while those on a placebo lost just 2%.

Tirzepatide is already a key ingredient in Lilly’s popular drugs Zepbound, for weight loss, and Mounjaro, for diabetes.

These findings not only support its effectiveness in controlling blood sugar but have also driven Eli Lilly’s stock up by more than 60% this year, with a 3% bump following the release of the study results.

In addition to its promising results, the drug’s safety profile remained consistent with previous trials. Common side effects included mild to moderate nausea, diarrhea, constipation, and vomiting, making it a manageable treatment for most patients.

The study’s findings suggest that tirzepatide could significantly delay the progression of prediabetes to Type 2 diabetes, offering hope for better long-term management of the condition.

The company’s stock is up over 60% this year and rose another 3% after the study’s results.